MGMT and glioblastoma: A possible explanation for these findings is that MGMT methylated tumors exhibit four more times the number of somatic mutations than MGMT-unmethylated GBM, making these tumors more immunogenic and more susceptible to the action of different immunotherapeutic approaches [61].